Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk.
BACKGROUND: Imbalances in tryptophan metabolism have been linked to cancer-related immune escape and implicated in several cancers, including lung cancer. METHODS: We conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) that included 89...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Association for Cancer Research Inc.
2014
|
| _version_ | 1797090829224902656 |
|---|---|
| author | Chuang, S Fanidi, A Ueland, P Relton, C Midttun, O Vollset, SE Gunter, M Seckl, M Travis, R Wareham, N Trichopoulou, A Lagiou, P Trichopoulos, D Peeters, P Bueno-de-Mesquita, H Boeing, H Wientzek, A Kuehn, T Kaaks, R Tumino, R Agnoli, C Palli, D Naccarati, A Aicua, E Sánchez, M |
| author_facet | Chuang, S Fanidi, A Ueland, P Relton, C Midttun, O Vollset, SE Gunter, M Seckl, M Travis, R Wareham, N Trichopoulou, A Lagiou, P Trichopoulos, D Peeters, P Bueno-de-Mesquita, H Boeing, H Wientzek, A Kuehn, T Kaaks, R Tumino, R Agnoli, C Palli, D Naccarati, A Aicua, E Sánchez, M |
| author_sort | Chuang, S |
| collection | OXFORD |
| description | BACKGROUND: Imbalances in tryptophan metabolism have been linked to cancer-related immune escape and implicated in several cancers, including lung cancer. METHODS: We conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) that included 893 incident lung cancer cases and 1,748 matched controls. Circulating levels of tryptophan and six of its metabolites were measured and evaluated in relation to lung cancer risk. RESULTS: Tryptophan (Ptrend = 2 × 10(-5)) and the kynurenine/tryptophan ratio (KTR; Ptrend = 4 × 10(-5)) were associated with lung cancer risk overall after adjusting for established risk factors. The ORs comparing the fifth and first quintiles (OR5th vs. 1st) were 0.52 [95% confidence interval (CI), 0.37-0.74] for tryptophan and 1.74 (95% CI, 1.24-2.45) for KTR. After adjusting for plasma methionine (available from previous work, which was strongly correlated with tryptophan), the associations of tryptophan (adjusted Ptrend = 0.13) and KTR (Ptrend = 0.009) were substantially attenuated. KTR was positively associated with squamous cell carcinoma, the OR5th vs. 1st being 2.83 (95% CI, 1.62-4.94, Ptrend = 3 × 10(-5)) that was only marginally affected by adjusting for methionine. CONCLUSIONS: This study indicates that biomarkers of tryptophan metabolism are associated with subsequent lung cancer risk. Although this result would seem consistent with the immune system having a role in lung cancer development, the overall associations were dependent on methionine, and further studies are warranted to further elucidate the importance of these metabolites in lung cancer etiology. IMPACT: This is the first prospective study investigating the tryptophan pathway in relation to lung cancer risk. |
| first_indexed | 2024-03-07T03:24:21Z |
| format | Journal article |
| id | oxford-uuid:b8859441-c873-4a4a-8990-dda39e9c7f83 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:24:21Z |
| publishDate | 2014 |
| publisher | American Association for Cancer Research Inc. |
| record_format | dspace |
| spelling | oxford-uuid:b8859441-c873-4a4a-8990-dda39e9c7f832022-03-27T04:56:31ZCirculating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b8859441-c873-4a4a-8990-dda39e9c7f83EnglishSymplectic Elements at OxfordAmerican Association for Cancer Research Inc.2014Chuang, SFanidi, AUeland, PRelton, CMidttun, OVollset, SEGunter, MSeckl, MTravis, RWareham, NTrichopoulou, ALagiou, PTrichopoulos, DPeeters, PBueno-de-Mesquita, HBoeing, HWientzek, AKuehn, TKaaks, RTumino, RAgnoli, CPalli, DNaccarati, AAicua, ESánchez, MBACKGROUND: Imbalances in tryptophan metabolism have been linked to cancer-related immune escape and implicated in several cancers, including lung cancer. METHODS: We conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) that included 893 incident lung cancer cases and 1,748 matched controls. Circulating levels of tryptophan and six of its metabolites were measured and evaluated in relation to lung cancer risk. RESULTS: Tryptophan (Ptrend = 2 × 10(-5)) and the kynurenine/tryptophan ratio (KTR; Ptrend = 4 × 10(-5)) were associated with lung cancer risk overall after adjusting for established risk factors. The ORs comparing the fifth and first quintiles (OR5th vs. 1st) were 0.52 [95% confidence interval (CI), 0.37-0.74] for tryptophan and 1.74 (95% CI, 1.24-2.45) for KTR. After adjusting for plasma methionine (available from previous work, which was strongly correlated with tryptophan), the associations of tryptophan (adjusted Ptrend = 0.13) and KTR (Ptrend = 0.009) were substantially attenuated. KTR was positively associated with squamous cell carcinoma, the OR5th vs. 1st being 2.83 (95% CI, 1.62-4.94, Ptrend = 3 × 10(-5)) that was only marginally affected by adjusting for methionine. CONCLUSIONS: This study indicates that biomarkers of tryptophan metabolism are associated with subsequent lung cancer risk. Although this result would seem consistent with the immune system having a role in lung cancer development, the overall associations were dependent on methionine, and further studies are warranted to further elucidate the importance of these metabolites in lung cancer etiology. IMPACT: This is the first prospective study investigating the tryptophan pathway in relation to lung cancer risk. |
| spellingShingle | Chuang, S Fanidi, A Ueland, P Relton, C Midttun, O Vollset, SE Gunter, M Seckl, M Travis, R Wareham, N Trichopoulou, A Lagiou, P Trichopoulos, D Peeters, P Bueno-de-Mesquita, H Boeing, H Wientzek, A Kuehn, T Kaaks, R Tumino, R Agnoli, C Palli, D Naccarati, A Aicua, E Sánchez, M Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. |
| title | Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. |
| title_full | Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. |
| title_fullStr | Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. |
| title_full_unstemmed | Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. |
| title_short | Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. |
| title_sort | circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk |
| work_keys_str_mv | AT chuangs circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT fanidia circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT uelandp circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT reltonc circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT midttuno circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT vollsetse circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT gunterm circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT secklm circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT travisr circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT warehamn circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT trichopouloua circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT lagioup circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT trichopoulosd circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT peetersp circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT buenodemesquitah circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT boeingh circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT wientzeka circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT kuehnt circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT kaaksr circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT tuminor circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT agnolic circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT pallid circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT naccaratia circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT aicuae circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk AT sanchezm circulatingbiomarkersoftryptophanandthekynureninepathwayandlungcancerrisk |